Investment in Maxion Therapeutics to drive antibody development for previously untreatable ion channel and GPCR-driven diseases
Invalid or expired token..
Seed funding will be used to scale the solution through the application of machine learning
AbbVie will pay DJS shareholders approximately $255 million in cash at closing for the acquisition of DJS
LifeArc portfolio company Ducentis BioTherapeutics acquired by Arcutis Biotherapeutics for up to $400 million
First exit for LifeArc Ventures, the largest investor in Ducentis, recognising the transformational potential of its science
LifeArc co-founded company RQ Bio signs licensing agreement with AstraZeneca worth up to $157m plus royalties for monoclonal antibodies against SARS-CoV-2
AstraZeneca granted exclusive worldwide licence to develop, manufacture and commercialise RQ Bio’s existing early-stage monoclonal antibodies (mAbs)…
LifeArc participates in Series A funding round for company developing pioneering new gene therapies for neurodegenerative diseases
Helping to progress an innovative gene therapy platform from the bench to a stage where it is progressing closer to the clinic.
Aims to transform the way diseases such as motor neurone disease are prevented, identified and treated.
10 innovative start-up companies working at the interface of biomedical and data science are to receive personalised…
LifeArc and partners announce a £13 million financing deal in Closed Loop Medicine to enable the company to develop further and faster.